Bristol-Myers Squibb (BMS), a BioPharma company focused to discover, develop and deliver medicines, has reported net sales of $4.8bn for the third quarter ended 30 September 2010, compared to $4.79bn for the same period in 2009.
BMS posted a net income of $949m for the third quarter 2010, or $0.55 per diluted share, compared to net income of $966m, or $0.45 per diluted share, for the comparable period in 2009.
For the nine months ended 30 September 2010, BMS posted net sales of $14.37bn, compared to $13.78bn for the year ago period.
The company has posted a net income of $2.62bn, or $1.51 per diluted share, for the nine months ended 30 September 2010, compared to net earnings of $2.59bn, or $1.21 per diluted share, for the year ago period.
BMS CEO Lamberto Andreotti said that the third quarter continued to highlight the excellent progress they were making with their pipeline.
"We delivered double-digit EPS growth in the quarter, presented encouraging data on apixaban and dapagliflozin, received regulatory approval in Japan for Orencia, and completed filings for regulatory review in the US, Europe and Japan," Andreotti said.
"We also completed our acquisition of ZymoGenetics, adding to our portfolio in Hepatitis C and demonstrating our continued focus on strategic transactions."